US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

GridAI Tech

3.42

+0.570020.00%

Post-market: 3.540.1237+3.62%19:56 EDT

Volume:259.76K

Turnover:854.14K

Market Cap:21.20M

PE:-0.34

High:3.52

Open:2.95

Low:2.80

Close:2.85

52wk High:5.84

52wk Low:1.06

Shares:6.20M

Float Shares:2.91M

Volume Ratio:2.74

T/O Rate:8.94%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-10.1052

EPS(LYR):-15.9831

ROE:--

ROA:--

PB:--

PE(LYR):-0.21

Loading ...

Overview Company News Filings

Company Profile

Company Name:

GridAI Tech

Exchange:

NASDAQ

Establishment Date:

- -

Employees:

- -

Office Location:

91 George St,Edinburgh,United Kingdom

Website:

http://www.enterothera.com

Zip Code:

EH2 3ESL

Phone:

- -

Fax:

- -

Introduction:

Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.

Directors

Name

Position

Jason Sawyer

Chief Executive Officer and Director

Edward J. Borkowski

Director

Geordan Pursglove

Director

Jack Syage

Director

Manpreet Uppal

Director

Shareholders

Name

Position

Jason Sawyer

Chief Executive Officer and Director

Anna Skowron

Interim Chief Financial Officer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/GRDX/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GRDX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GRDX\",,,,,undefined,":{"symbol":"GRDX","market":"US","secType":"STK","nameCN":"GridAI Tech","latestPrice":3.42,"timestamp":1778270400000,"preClose":2.85,"halted":0,"volume":259764,"hourTrading":{"tag":"盘后","latestPrice":3.5437,"preClose":3.42,"latestTime":"19:56 EDT","volume":2587,"amount":8957.9,"timestamp":1778284572305,"change":0.1237,"changeRate":0.03617,"amplitude":0.055556},"delay":0,"changeRate":0.19999999999999993,"floatShares":2907100,"shares":6200051,"eps":-10.1052,"marketStatus":"Market Closed","change":0.57,"latestTime":"05-08 16:00:00 EDT","open":2.95,"high":3.52,"low":2.797,"amount":854136.5804292,"amplitude":0.253684,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-10.1052,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1778486400000},"marketStatusCode":7,"adr":0,"listingDate":1476158400000,"exchange":"NASDAQ","adjPreClose":2.85,"preHourTrading":{"tag":"盘前","latestPrice":2.95,"preClose":2.85,"latestTime":"08:36 EDT","volume":180,"amount":474.364422,"timestamp":1778243801175,"change":0.1,"changeRate":0.035088,"amplitude":0.111018},"postHourTrading":{"tag":"盘后","latestPrice":3.5437,"preClose":3.42,"latestTime":"19:56 EDT","volume":2587,"amount":8957.9,"timestamp":1778284572305,"change":0.1237,"changeRate":0.03617,"amplitude":0.055556},"volumeRatio":2.743470820622436},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GRDX\",,,,,undefined,":{"symbol":"GRDX","floatShares":2907100,"roa":"--","roe":"--","lyrEps":-15.9831,"volumeRatio":2.743470820622436,"shares":6200051,"dividePrice":0,"high":3.52,"amplitude":0.253684,"preClose":2.85,"low":2.797,"week52Low":1.056,"pbRate":"--","week52High":5.84,"institutionHeld":0,"latestPrice":3.42,"eps":-10.1052,"divideRate":0,"volume":259764,"delay":0,"ttmEps":-10.1052,"open":2.95,"prevYearClose":4.66,"prevWeekClose":2.52,"prevMonthClose":2.51,"prevQuarterClose":2.02,"fiveDayClose":2.52,"twentyDayClose":2.09,"sixtyDayClose":3.13},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GRDX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-01","symbol":"GRDX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1777608000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-11-19","symbol":"GRDX","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763528400000,"reportTimeType":"post","actualEps":-0.64},{"market":"US","date":"2025-08-18","symbol":"GRDX","defaultRemindTime":1755523800000,"type":"split","dateTimestamp":1755489600000,"forFactor":3,"toFactor":1,"ratio":3},{"market":"US","date":"2025-08-14","symbol":"GRDX","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"","actualEps":-0.14},{"market":"US","date":"2025-05-15","symbol":"GRDX","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"","actualEps":-0.21}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GRDX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GRDX\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":1962880793,"address":"91 George St,Edinburgh,United Kingdom","zipCode":"EH2 3ESL"},"stockCompanyDetail":{"websiteUrl":"http://www.enterothera.com","stockEarnings":[{"period":"1week","weight":0.1355},{"period":"1month","weight":0.3194},{"period":"3month","weight":-0.0206},{"period":"6month","weight":-0.2692},{"period":"1year","weight":1.5066},{"period":"ytd","weight":-0.3884}],"compareEarnings":[{"period":"1week","weight":0.018},{"period":"1month","weight":0.1098},{"period":"3month","weight":0.0593},{"period":"6month","weight":0.0903},{"period":"1year","weight":0.3037},{"period":"ytd","weight":0.0728}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.3,"avgChangeRate":0.057618},{"month":2,"riseRate":0.1,"avgChangeRate":-0.069297},{"month":3,"riseRate":0.2,"avgChangeRate":-0.100676},{"month":4,"riseRate":0.5,"avgChangeRate":-0.1069},{"month":5,"riseRate":0.4,"avgChangeRate":-0.052002},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.094933},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.226619},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.05499},{"month":9,"riseRate":0.222222,"avgChangeRate":-0.070567},{"month":10,"riseRate":0.333333,"avgChangeRate":0.014204},{"month":11,"riseRate":0.3,"avgChangeRate":-0.121901},{"month":12,"riseRate":0.7,"avgChangeRate":0.106774}],"exchange":"NASDAQ","name":"GridAI Tech","nameEN":"GridAI Tech"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"GRDX\",market:\"US\",,,undefined,":{"directors":[{"name":"Jason Sawyer","position":"Chief Executive Officer and Director"},{"name":"Edward J. Borkowski","position":"Director"},{"name":"Geordan Pursglove","position":"Director"},{"name":"Jack Syage","position":"Director"},{"name":"Manpreet Uppal","position":"Director"}],"executives":[{"name":"Jason Sawyer","position":"Chief Executive Officer and Director"},{"name":"Anna Skowron","position":"Interim Chief Financial Officer"}]}}}